Court Halts Boehringer’s COPD Inhaler Comparative Claims Vs. GSK Products
GlaxoSmithKline win shows value of going to court as US FDA is less likely to take action against comparative promotions. Court was swayed by GSK survey showing likely harm caused by ‘false and misleading statements not supported by scientific studies.’
You may also be interested in...
US FDA's wariness of taking enforcement action against Rx drug promotions may lead to more suits like GSK's. Complaint says healthcare providers are switching COPD patients to BI's Respimat inhaler in response to BI's marketing campaign.
Companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.
Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.